SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Posted: August 14, 2024 at 2:37 am

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 -

Visit link:
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Related Posts